- Home
- ARWR vs CLVT Comparison
ARWR vs CLVT Comparison
Compare ARWR & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- CLVT
- Stock Information
- Founded
- ARWR 2003
- CLVT 2016
- Country
- ARWR United States
- CLVT United Kingdom
- Employees
- ARWR N/A
- CLVT N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- CLVT EDP Services
- Sector
- ARWR Health Care
- CLVT Technology
- Exchange
- ARWR Nasdaq
- CLVT Nasdaq
- Market Cap
- ARWR 2.5B
- CLVT 2.8B
- IPO Year
- ARWR 1993
- CLVT N/A
- Fundamental
- Price
- ARWR $22.03
- CLVT $4.35
- Analyst Decision
- ARWR Buy
- CLVT Hold
- Analyst Count
- ARWR 8
- CLVT 4
- Target Price
- ARWR $43.14
- CLVT $4.83
- AVG Volume (30 Days)
- ARWR 2.5M
- CLVT 4.4M
- Earning Date
- ARWR 08-07-2025
- CLVT 07-30-2025
- Dividend Yield
- ARWR N/A
- CLVT N/A
- EPS Growth
- ARWR N/A
- CLVT N/A
- EPS
- ARWR N/A
- CLVT N/A
- Revenue
- ARWR $572,976,000.00
- CLVT $2,500,300,000.00
- Revenue This Year
- ARWR $22,306.37
- CLVT N/A
- Revenue Next Year
- ARWR N/A
- CLVT N/A
- P/E Ratio
- ARWR N/A
- CLVT N/A
- Revenue Growth
- ARWR 2816.20
- CLVT N/A
- 52 Week Low
- ARWR $9.57
- CLVT $3.04
- 52 Week High
- ARWR $27.34
- CLVT $7.15
- Technical
- Relative Strength Index (RSI)
- ARWR 68.08
- CLVT 54.76
- Support Level
- ARWR $20.45
- CLVT $4.38
- Resistance Level
- ARWR $22.75
- CLVT $4.56
- Average True Range (ATR)
- ARWR 1.05
- CLVT 0.14
- MACD
- ARWR 0.26
- CLVT 0.02
- Stochastic Oscillator
- ARWR 86.98
- CLVT 72.14
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.